Yoda Pharmaceuticals Company Description

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders.

The company’s flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy.

It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury.

Yoda Pharmaceuticals Inc. was incorporated in 2019 and is based in Grand Cayman, the Cayman Islands.

Yoda Pharmaceuticals Inc.

Country	Cayman Islands
Founded	2019
Industry	Pharmaceutical Preparations
CEO	Yufeng Tseng

Contact Details

Address: The Grand Pavilion Commercial Centre Grand Cayman, KY1- 1208 Cayman Islands
Website	yodapharma.com

Stock Details

Ticker Symbol	7829
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
SIC Code	2834

Key Executives

Name	Position
Yufeng Tseng	Chief Executive Officer